For the last few decades, aesthetic dermatology has become increasingly popular. Most of our patients want to enhance their look without downtime.
The increasing need for long-lasting injectable soft tissue fillers for the treatment of wrinkles and folds requires a critical discussion of the biocompatibility on a scientific background.
Since 1996, hyaluronic acid (HA) has been launched onto the market in Europe. Since then, different companies proposed their HAs. Biomatrix (NJ, USA) proposes an animal-derived HA (from rooster comb). Q–Med AB (Uppsala, Sweden) and LEA-DERM (Paris, France) are the main companies to have a nonanimal HA.
Poly-L-lactic acid (PLA) New-Fill* is one of the latest implants commercialized among bioresorbable fillers. This synthetic polymer is biocompatible, biodegradable, immunologically inert, and free from toxicity.